Announced Thu, 9 Jul · 08:45 IST
Biocon announces publication of Yesafili biosimilar clinical data in peer-reviewed journals
Compliance View source PDF
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+5.2%1-day move
₹397.55
prior close
₹399.80
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1+0.3+1.4+1.5+5.2+3.8+9.9+9.3+11.2+9.7————
Up moveDown movePending
AI summary
Biocon announced publication of two pivotal clinical studies for Yesafili (aflibercept-jbvf), its biosimilar to Eylea, in peer-reviewed journals. Data from the Phase III INSIGHT program showed comparable safety and efficacy between Yesafili and reference aflibercept in diabetic macular edema patients, including those who switched treatments. Yesafili received FDA approval with interchangeable designation in May 2024. The company is preparing for US launch.
Likely market impact
Positive clinical milestone strengthens evidence ahead of US launch of Yesafili, supporting Biocon's biosimilars business growth.